A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Anna Kalff, Jake Shortt, Flora Yuen, John Reynolds, Hang Quach, Craig Wallington-Beddoe, Patricia Walker, Simon Harrison, Dunn Rosanne, Andrew Spencer

Research output: Contribution to journalMeeting Abstractpeer-review

Abstract

BACKGROUND: KappaMab is a chimeric IgG1 monoclonal antibody specific for Kappa Myeloma antigen (KMA), a tumour specific cell antigen exclusively expressed on the surface of kappa restricted MM cells. Early safety and efficacy signals seen with single-agent treatment in phase I/II studies in conjunction with observations that IMiD®-treatment upregulates the KMA target and enhances effector cell cytotoxicity, provide rationale for this proof-of principal immune-oncology (IO) approach in a kappa restricted MM population.
Original languageEnglish
Number of pages4
JournalBlood
Volume134
Issue numberSupplement 1
DOIs
Publication statusPublished - 13 Nov 2019
Event61st ASH Annual Meeting - Orlando, United States
Duration: 7 Dec 201910 Dec 2019
Conference number: 61

Keywords

  • dexamethasone
  • lenalidomide
  • multiple myeloma
  • Antigens
  • hematotoxicity
  • thalidomide
  • abdominal pain
  • Kappa
  • Kappa Myeloma antigen (KMA)

Fingerprint

Dive into the research topics of 'A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)'. Together they form a unique fingerprint.

Cite this